DK0964874T3 - CAML-bindende lymfocytoverfladereceptor, nukleinsyrer, som koder derfor, og fremgangsmåder til anvendelse deraf - Google Patents

CAML-bindende lymfocytoverfladereceptor, nukleinsyrer, som koder derfor, og fremgangsmåder til anvendelse deraf

Info

Publication number
DK0964874T3
DK0964874T3 DK98908948T DK98908948T DK0964874T3 DK 0964874 T3 DK0964874 T3 DK 0964874T3 DK 98908948 T DK98908948 T DK 98908948T DK 98908948 T DK98908948 T DK 98908948T DK 0964874 T3 DK0964874 T3 DK 0964874T3
Authority
DK
Denmark
Prior art keywords
caml
methods
nucleic acids
encoding nucleic
surface receptor
Prior art date
Application number
DK98908948T
Other languages
Danish (da)
English (en)
Inventor
Richard J Bram
Bulow Gotz Von
Original Assignee
St Jude Childrens Res Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Jude Childrens Res Hospital filed Critical St Jude Childrens Res Hospital
Application granted granted Critical
Publication of DK0964874T3 publication Critical patent/DK0964874T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK98908948T 1997-03-03 1998-03-03 CAML-bindende lymfocytoverfladereceptor, nukleinsyrer, som koder derfor, og fremgangsmåder til anvendelse deraf DK0964874T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/810,572 US5969102A (en) 1997-03-03 1997-03-03 Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
PCT/US1998/004270 WO1998039361A1 (fr) 1997-03-03 1998-03-03 Recepteur de surface de lymphocyte liant une cyclophiline de modulation de signal de calcium (caml), acides nucleiques codant pour celle-ci, et procedes d'utilisation de ceux-ci

Publications (1)

Publication Number Publication Date
DK0964874T3 true DK0964874T3 (da) 2007-12-10

Family

ID=25204137

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98908948T DK0964874T3 (da) 1997-03-03 1998-03-03 CAML-bindende lymfocytoverfladereceptor, nukleinsyrer, som koder derfor, og fremgangsmåder til anvendelse deraf

Country Status (11)

Country Link
US (7) US5969102A (fr)
EP (3) EP0964874B1 (fr)
JP (1) JP3594975B2 (fr)
AT (1) ATE373012T1 (fr)
AU (1) AU732119B2 (fr)
CA (1) CA2284078C (fr)
DE (1) DE69838417T2 (fr)
DK (1) DK0964874T3 (fr)
ES (2) ES2552095T3 (fr)
PT (1) PT964874E (fr)
WO (1) WO1998039361A1 (fr)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6830751B1 (en) 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US20060067933A1 (en) * 1999-01-07 2006-03-30 Gross Jane A Soluble receptor BR43x2 and methods of using
DE60043626D1 (de) * 1999-01-07 2010-02-11 Zymogenetics Inc Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2
US7833529B1 (en) * 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
AU2005200008B2 (en) * 1999-01-07 2008-03-06 Zymogenetics, Inc. Soluble receptor BR43x2 and methods of using
US20050100548A1 (en) * 2001-07-24 2005-05-12 Biogen Idec Ma Inc. BAFF, inhibitors thereof and their use in the modulation of B-cell response
BR0007719A (pt) * 1999-01-25 2001-11-13 Biogen Inc Baff, agentes de bloqueio relacionados e uso dosmesmos no estìmulo e na inibição de células b e deimunoglobulinas em respostas imunológicas
US20030095967A1 (en) * 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
WO2000058362A1 (fr) * 1999-03-26 2000-10-05 Human Genome Sciences, Inc. Nouvelles proteines capables de liaison avec la neutrokine alpha et procedes bases sur lesdites proteines
US20030022233A1 (en) * 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
UA75049C2 (uk) * 1999-08-17 2006-03-15 Байоджен Айдек Ма Інк. Фармацевтична композиція, що містить поліпептид, який являє собою білковий фактор дозрівання в-клітин (всма), що зв'язується з фактором активації в-клітин (baff), спосіб інгібування росту в-клітин, спосіб лікування аутоімунного захворювання, спосіб лікування гіпертонії, спосіб інгібування запалення та спосіб модулювання імунної відповіді у ссавця за допомогою всма
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
CA2400214A1 (fr) * 2000-02-11 2001-11-15 Amgen Inc. Recepteur de la famille tnf
CA2396793A1 (fr) * 2000-02-16 2001-08-23 Genentech, Inc. Utilisation d'agonistes ou d'antagonistes pour moduler l'activite de molecules associees au tnf
US6969519B2 (en) * 2000-03-10 2005-11-29 Human Genome Sciences, Inc. Methods of using an agonistic antibody human tumor necrosis factor receptor (TR17)
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
JP2004513876A (ja) * 2000-04-27 2004-05-13 バイオジェン　インコーポレーテッド 抗−腫瘍剤としてのｔａｃｉ
US20040013674A1 (en) * 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
EP1746106A3 (fr) * 2000-04-27 2007-03-14 Biogen Idec MA Inc. TACI utilisée en tant qu'agent antitumoral
US20020086018A1 (en) * 2000-05-12 2002-07-04 Theill Lars Eyde Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI
CA2413160A1 (fr) * 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Facteur de necrose tumorale humain delta et epsilon
AU2001268427B2 (en) * 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
NZ548265A (en) * 2000-07-07 2008-06-30 Eisai R&D Man Co Ltd Antifungal compounds and agents able to inhibit transport of the GPI-anchored protein to the cell wall
PT1303293E (pt) 2000-07-27 2009-03-11 Genentech Inc Administração sequencial de cpt-11 e polipéptido apo-2l
WO2002016411A2 (fr) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Polypeptides de fixation et procedes associes
UA83458C2 (uk) * 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
AU2002215753A1 (en) * 2000-12-07 2002-06-18 The University Of British Columbia Caml-binding peptides
US20030012783A1 (en) * 2001-02-20 2003-01-16 Wayne Kindsvogel Antibodies that bind both BCMA and TACI
ATE549354T1 (de) 2001-05-11 2012-03-15 Amgen Inc Peptide und damit zusammenhängende an tall-1 bindende moleküle
BRPI0209933B8 (pt) 2001-05-24 2021-05-25 Zymogenetics Inc proteína de fusão, e, molécula de ácido nucleico
PH12012502440A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
DE10131922A1 (de) * 2001-07-02 2003-01-30 Brahms Ag Verwendung des Calcineurin B Homologen Proteins (CHP) für die Diagnose und Therapie von Entzündungserkrankungen und Sepsis
WO2003066661A2 (fr) 2001-07-03 2003-08-14 Genentech, Inc. Anticorps humains du dr4 et utilisations
EP1414948B1 (fr) * 2001-07-10 2009-09-16 Biogen Idec Inc. Inhibition de l'apoptose et amelioration de la performance cellulaire
BR0211614A (pt) * 2001-08-03 2006-10-31 Genentech Inc polipeptìdeo tacis e br3 e empregos dos mesmos
US6551615B1 (en) * 2001-10-18 2003-04-22 M/S. Strides Arcolab Limited Dexibuprofen-containing soft gelatin capsules and process for preparing the same
AU2003221256A1 (en) * 2002-02-21 2003-09-09 Biogen Idec Ma Inc. Use of bcma as an immunoregulatory agent
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
US8025873B2 (en) * 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US6890725B2 (en) * 2002-07-23 2005-05-10 Rigel Pharmaceuticals, Inc. Modulators of B-lymphocyte activation, myosin-1F compositions and methods of use
CN1692127A (zh) * 2002-07-25 2005-11-02 健泰科生物技术公司 Taci抗体及其用途
EP1558278B1 (fr) * 2002-10-11 2009-09-02 ZymoGenetics, Inc. Production de proteines hybrides homo-trimeriques
WO2004094620A2 (fr) 2003-03-28 2004-11-04 Biogen Idec Ma Inc. Recepteurs baff tronques
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
PL1631313T3 (pl) 2003-06-05 2015-08-31 Genentech Inc Terapia skojarzona zaburzeń z komórek B
US7211407B2 (en) * 2003-07-15 2007-05-01 Chan Test, Inc. High throughput assay systems and methods for identifying agents that alter surface expression of integral membrane proteins
CA2554526A1 (fr) * 2004-01-29 2005-08-18 Genentech, Inc. Variants du domaine extracellulaire de bcma et utilisations de ceux-ci
ATE517914T1 (de) 2004-03-08 2011-08-15 Zymogenetics Inc Dimere fusionsproteine und materialien und verfahren zu deren herstellung
CA2585927A1 (fr) * 2004-11-04 2006-05-18 Genentech, Inc. Polypeptides se liant avec baff et/ou april
AU2006209237B2 (en) * 2005-01-28 2010-06-24 Biogen Ma Inc. Use of BAFF to treat Th2-mediated conditions
AU2006278229B2 (en) * 2005-08-09 2011-10-27 Ares Trading S.A. Methods for treating B-cell malignancies using TACI-Ig fusion molecule
EP1922079A2 (fr) * 2005-08-09 2008-05-21 ZymoGenetics, Inc. Procedes pour le traitement et la prevention de proliferation cellulaire anormale par le biais de molecules de fusion taci
EA015860B1 (ru) * 2005-10-13 2011-12-30 Хьюман Дженом Сайенсиз, Инк. Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
AR056806A1 (es) 2005-11-14 2007-10-24 Amgen Inc Moleculas quimericas de anticuerpo rankl- pth/ pthrp
WO2007062090A2 (fr) * 2005-11-23 2007-05-31 Genentech, Inc. Procedes et compositions lies a des analyses de lymphocytes b
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
JP2009537563A (ja) * 2006-05-15 2009-10-29 アレス トレーディング ソシエテ アノニム Ｔａｃｉ融合分子を使用する自己免疫疾患を治療するための方法
DK2061803T4 (da) 2006-08-28 2022-12-05 Ares Trading Sa Fremgangsmåde til oprensning af fc-holdige proteiner
EA017733B1 (ru) * 2006-08-28 2013-02-28 Арес Трейдинг С.А. СПОСОБ ОЧИСТКИ Fc-СЛИТЫХ БЕЛКОВ
CA2674213A1 (fr) 2007-01-26 2008-07-31 Merck Serono S.A. Purification de proteines hybrides fc-tact utilisant la technologie a base de corps huileux
EP2200631A1 (fr) 2007-10-16 2010-06-30 Zymogenetics, Inc. Combinaison d'agents d'inhibition de blys et d'agents anti-cd 20 pour le traitement d'une maladie auto-immune
WO2010093993A2 (fr) * 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Utilisation d'antagonistes de la protéine stimulant les lymphocytes b afin de favoriser la tolérance aux greffes
WO2011109280A1 (fr) 2010-03-05 2011-09-09 Lerner Research Institute Procédés et compositions permettant de traiter les troubles d'origines immunes
EP2934532B1 (fr) 2012-12-20 2019-10-23 Purdue Research Foundation Cellules t exprimant un récepteur d'antigène chimérique et produits thérapeutiques anticancéreux
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
CN110612119B (zh) 2017-02-07 2024-10-29 西雅图儿童医院（Dba西雅图儿童研究所） 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
CN111655280B (zh) * 2017-09-01 2025-01-14 达纳-法伯癌症研究所股份有限公司 用于治疗癌症的bcma和taci抗原特异的免疫原性肽
JP7549303B2 (ja) 2018-01-22 2024-09-11 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞の使用方法
SG11202007426XA (en) 2018-02-06 2020-09-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
CN112105382A (zh) 2018-02-23 2020-12-18 恩多塞特公司 用于car t细胞疗法的顺序方法
AU2021217003A1 (en) 2020-02-04 2022-09-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Anti-dinitrophenol chimeric antigen receptors
JP7748393B2 (ja) 2020-05-08 2025-10-02 アルパイン イミューン サイエンシズ インコーポレイテッド Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法
WO2022131889A1 (fr) * 2020-12-16 2022-06-23 주식회사 굳티셀 Utilisation de protéine taci
US20240002468A1 (en) 2021-08-10 2024-01-04 Remegen Co., Ltd. Method for treating iga nephropathy with taci-fc fusion protein
AU2022358137B2 (en) 2021-09-30 2026-02-12 Remegen Co., Ltd. Method for treating sjogren’s syndrome using taci-fc fusion protein
IL317055A (en) 2022-06-08 2025-01-01 Remegen Co Ltd METHOD FOR TREATING MYASTHENIA GRAVIS WITH TACI-FC FUSION PROTEIN
JP2025532251A (ja) 2022-09-30 2025-09-29 レメゲン シーオー．，エルティーディー． ＴＡＣＩ－Ｆｃ融合タンパク質を用いた膜性腎症の治療方法
EP4527375A1 (fr) 2022-12-07 2025-03-26 RemeGen Co., Ltd. Préparation pharmaceutique liquide de protéine de fusion taci-fc
WO2025007943A1 (fr) 2023-07-06 2025-01-09 荣昌生物制药(烟台)股份有限公司 Procédé de traitement de la vascularite associée aux anca à l'aide d'une protéine de fusion taci-fc

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
NL7807532A (nl) 1978-07-13 1980-01-15 Akzo Nv Metaal-immunotest.
NL8000173A (nl) 1980-01-11 1981-08-03 Akzo Nv Toepassing van in water dispergeerbare, hydrofobe kleurstoffen als label in immunochemische testen.
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4703017C1 (en) 1984-02-14 2001-12-04 Becton Dickinson Co Solid phase assay with visual readout
US4751181A (en) * 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
CA1338860C (fr) 1987-04-13 1997-01-21 Peter Parker Marquage de proteines a l'aide de radio-isotopes
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3882058T2 (de) 1987-02-27 1994-01-13 Eastman Kodak Co Immunoreaktives Reagens, Verfahren zu seiner Herstellung und seine Verwendung zur Bestimmung einer immunoreaktiven Spezies.
EP0280559B1 (fr) 1987-02-27 1993-10-20 EASTMAN KODAK COMPANY (a New Jersey corporation) Essai immunologique d'agglutination et trousse de réactifs pour la détermination d'une espèce immunollogique polyvalente utilisant une solution saline de nettoyage tamponnée
US4857453A (en) 1987-04-07 1989-08-15 Syntex (U.S.A.) Inc. Immunoassay device
ATE195022T1 (de) 1987-04-27 2000-08-15 Unilever Nv Spezifische bindungstestverfahren
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
IL92124A (en) 1988-10-28 1996-10-31 Sidney Pestka Recombinant proteins modified to contain post-phosphorylation that do not occur in nature
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5139749A (en) 1990-06-22 1992-08-18 Tas, Inc. Fluidized calcining process
DE69123241T2 (de) 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
WO1992013878A2 (fr) 1991-02-07 1992-08-20 Board Of Trustees Of The University Of Illinois Produits mimetiques de conformation restreinte de tours beta et bombements beta, et peptides les contenant
JP3394777B2 (ja) 1993-05-27 2003-04-07 セレクタイド コーポレーション 位相学的に分離された、コードされた固相ライブラリー
CA2168202A1 (fr) 1993-07-30 1995-03-16 Joseph Dougherty Transfert genique efficace aboutissant a des lymphocytes primaires
US5650550A (en) * 1993-10-01 1997-07-22 The United States Of America As Represented By The Department Of Health And Human Services Mutant mice having a deficit of functional estrogen receptors
WO1995028494A1 (fr) 1994-04-15 1995-10-26 Targeted Genetics Corporation Proteine de fusion d'apport de gene
US5523227A (en) * 1994-06-17 1996-06-04 The Board Of Trustees Of The Leland Stanford Junior Univ. DNA encoding calcium-signal modulating cyclophilin ligand
DE69535634T2 (de) * 1994-12-15 2008-08-28 Yeda Research And Development Co., Ltd. Modulatoren der funktion des fas/ap01 rezeptors
US6077947A (en) 1995-02-02 2000-06-20 Cell Genesys, Inc. DNA encoding an intracellular chimeric receptor comprising Janus kinase
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6103521A (en) 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US6685728B2 (en) * 2002-01-25 2004-02-03 Stryker Endoscopy Threaded suture anchor and method of use
US9002545B2 (en) 2011-01-07 2015-04-07 Wabtec Holding Corp. Data improvement system and method

Also Published As

Publication number Publication date
US20030082173A1 (en) 2003-05-01
ES2292201T3 (es) 2008-03-01
EP0964874A1 (fr) 1999-12-22
US20090226473A1 (en) 2009-09-10
DE69838417D1 (de) 2007-10-25
JP2001518080A (ja) 2001-10-09
US20050183148A1 (en) 2005-08-18
ATE373012T1 (de) 2007-09-15
JP3594975B2 (ja) 2004-12-02
EP1632500B1 (fr) 2015-08-05
DE69838417T2 (de) 2008-05-29
AU732119B2 (en) 2001-04-12
WO1998039361A1 (fr) 1998-09-11
US6500428B1 (en) 2002-12-31
US20060101529A1 (en) 2006-05-11
AU6685498A (en) 1998-09-22
EP0964874B1 (fr) 2007-09-12
US6316222B1 (en) 2001-11-13
ES2552095T3 (es) 2015-11-25
CA2284078A1 (fr) 1998-09-11
CA2284078C (fr) 2014-09-09
PT964874E (pt) 2007-12-21
US5969102A (en) 1999-10-19
EP1632500A3 (fr) 2007-05-30
US7355005B2 (en) 2008-04-08
EP1632500A2 (fr) 2006-03-08
EP2292654A3 (fr) 2012-07-25
EP2292654A2 (fr) 2011-03-09

Similar Documents

Publication Publication Date Title
DK0964874T3 (da) CAML-bindende lymfocytoverfladereceptor, nukleinsyrer, som koder derfor, og fremgangsmåder til anvendelse deraf
NO20010320D0 (no) Nukleinsyrer som koder for en G-proteinkoblet reseptor som er involvert i sensorisk transduksjon
NO961115L (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
ATE358178T1 (de) Modulierung der tnf-rezeptoraktivität
DK1482042T3 (da) Aktive og inaktive CC-kemokinreceptorer og nukleinsyremolekyler der koder for receptoren
FI972390A0 (fi) Sytokiini nimeltä Lerk-7
DK1860187T3 (da) Apo-2-receptor
DE69434908D1 (de) Rezeptor an der oberfläche von aktivierten t-zellen:act4
DE69431805D1 (de) Struktur höherer ordnung und bindung von peptidnukleinsäuren
NO961796D0 (no) Rekombinante fedme (ob) proteiner
DK0692025T3 (da) Gærceller, der er konstrueret således, at de producerer surrogater for proteiner i feromonsystemet, og anvendelser deraf
PL336306A1 (en) Proteinous fusions of tgf-beta ii type receptor with a constant immunoglobulin area
NO963818L (no) Forhöyet utskillelse av polypeptider
BR9912545A (pt) ácidos nucleicos codificando um receptorcopulado a proteìna g envolvido em transduçãosensorial
AU1846995A (en) Heterologous g protein coupled receptors expressed in yeast, their fusion with g proteins and use thereof in bioassay
ES557188A0 (es) Un metodo para obtener un polipeptido complementario de al menos una porcion de un peptido o proteina original
DE60335216D1 (de) Adiponektin-rezeptor und dafür kodierendes gen
NO970740L (no) Glutamat reseptor
ATE212055T1 (de) Östrogen-rezeptor
DK0840615T3 (da) Kemokin-bindende protein og fremgangsmåder til anvendelse deraf
AR010041A1 (es) Agonistas multifuncionales quimericos de receptores de hematopoyetina
NO973422D0 (no) Recombinant C140-reseptor, dens agonister og antagonister og nukleinsyrer som koder for reseptoren
DK0968288T3 (da) z219a, en human homolog til 2-19 protein
IL153818A0 (en) Method with a wide range of applications, for identifying modulators of g-protein-coupled receptors
SE9701010D0 (sv) Antibody